Haematologica
Selective lymphodepletion underlies the efficacy of horse anti-thymocyte globulin-based immunosuppressive therapy in aplastic anemia.
Emma S Pool, Cilia R Pothast, Shannah M Gennesse, Esther H M Van Egmond, Julia M Giezen, Sabrina A J Veld, René E M Toes, Frits Koning, Constantijn J M Halkes, Mirjam H M Heemskerk, Dirk Jan A R Moes, Jennifer M-L Tjon
Published: 202610.3324/haematol.2025.300002
Abstract
Horse-derived anti-thymocyte globulin (ATGAM) in combination with long-term ciclosporin is the first-line treatment for most immune-mediated aplastic anemia (AA) patients. The exact impact of this immunosuppressive therapy (IST) on hematological reco…
Preview only. Read the full abstract at the source